Correlation between COVID-19 severity and immune responses after six months

Simon Collins, HIV i-Base

The strength and durability of immune responses after recovery from COVID-19 helps model the future public health risks and can also inform the timing of vaccination.

This study reports the duration of humoral and cellular immunity in 97 participants from three stages: asymptomatic (n=14), symptomatic/non-pneumonic (n=42), and pneumonic (n=41).

Six months after diagnosis, overall anti-SARS-CoV-2 IgG and neutralising antibody (NAb) titers were positive in 66.7% and 86.9%, in the combined non-pneumonic and pneumonic groups respectively. 

respectively. Those with this sustained humoral immunity were more likely to be older, with longer viral shedding and pneumonia – and were also more likely to have a SARC-CoV-2 specific T-cell response.


Noh JY et al. Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19. JID, jiab124, DOI: 10.1093/infdis/jiab124. (4 March 2021).

This report was first published on 17 May 2020.

Links to other websites are current at date of posting but not maintained.